Controversial cancer patent upheld by EPO
An EPO Technical Board of Appeal has maintained a controversial patent for diagnosing a predisposition for breast and ovarian cancer in amended form
The patent, number 699,754, was filed by Myriad Genetics, the University of Utah Research Foundation and the USA. It was published in 1996.
As approved by the Board, it covers diagnostic methods for detecting a predisposition...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.